{"schema_version":"secwatch.filing_event.v1","accession":"0000950170-24-002636","form_type":"8-K","ticker":"RXST","cik":"0001111485","company_name":"RxSight, Inc.","filed_at":"2024-01-08T23:59:59+00:00","discovered_at":"2026-05-14T18:03:23.393439+00:00","generated_at":"2026-06-07T01:59:04.592082+00:00","sec_items":["2.02","9.01"],"event_type":"earnings","sentiment":"positive","materiality_score":0.85,"calibrated_materiality_score":0.85,"confidence":"high","headline":"RxSight Q4 rev ~$28.6M (+78% YoY); FY2023 rev ~$89.1M (+82%); guides FY2024 rev $128-135M","bullets":["Q4 2023 rev ~$28.6M (+78% YoY) driven by 77 LDD placements and 18,071 LALs sold.","FY2023 rev ~$89.1M (+82% YoY); 666 LDD installed base; 54,873 LALs sold.","Cash and investments ~$127.2M as of Dec 31, 2023.","FY2024 revenue guidance of $128-135M (+44-52% YoY); gross margin 65-67%.","Expects 2024 operating expenses $125-128M; non-cash expenses $22-25M."],"urls":{"canonical":"https://secwatch.observer/filing/0000950170-24-002636","json":"https://secwatch.observer/filing/0000950170-24-002636.json","markdown":"https://secwatch.observer/filing/0000950170-24-002636.md","text":"https://secwatch.observer/filing/0000950170-24-002636.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1111485/000095017024002636/0000950170-24-002636-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1111485/000095017024002636/rxst-20240107.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-06-07T01:59:04.592082+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[{"claim_id":"2c61aa6074a99dcf20bb4380904ffadb0d61703b","claim":"RxSight, Inc. reported the fourth quarter ended December 31, 2023 results: revenue approximately $28.6 million.","evidence_excerpt":"Preliminary unaudited fourth quarter 2023 revenue is expected to be approximately $28.6 million","evidence_source":"SEC 8-K Item 2.02","evidence_url":"https://www.sec.gov/Archives/edgar/data/1111485/000095017024002636/0000950170-24-002636-index.htm","confidence":0.9,"family_label":"Earnings Releases","details":[{"label":"Period","value":"the fourth quarter ended December 31, 2023"},{"label":"Revenue","value":"approximately $28.6 million"},{"label":"Result","value":"preliminary results"}],"fact_type":"earnings_release"},{"claim_id":"494adb4b6e00ca6a16c2b9763e312dab1c196974","claim":"RxSight, Inc. reported the fiscal year ended December 31, 2023 results: revenue approximately $89.1 million.","evidence_excerpt":"Preliminary unaudited 2023 fiscal year revenue is expected to be approximately $89.1 million","evidence_source":"SEC 8-K Item 2.02","evidence_url":"https://www.sec.gov/Archives/edgar/data/1111485/000095017024002636/0000950170-24-002636-index.htm","confidence":0.9,"family_label":"Earnings Releases","details":[{"label":"Period","value":"the fiscal year ended December 31, 2023"},{"label":"Revenue","value":"approximately $89.1 million"},{"label":"Result","value":"preliminary results"}],"fact_type":"earnings_release"},{"claim_id":"58267f75833b9801fb0342c52e98731f7d13fbd9","claim":"RxSight, Inc. reported the fiscal year ending December 31, 2024 results: revenue $128.0 million to $135.0 million. Guidance initiated.","evidence_excerpt":"RxSight anticipates full-year 2024 revenue of $128.0 million to $135.0 million","evidence_source":"SEC 8-K Item 2.02","evidence_url":"https://www.sec.gov/Archives/edgar/data/1111485/000095017024002636/0000950170-24-002636-index.htm","confidence":0.9,"family_label":"Earnings Releases","details":[{"label":"Period","value":"the fiscal year ending December 31, 2024"},{"label":"Revenue","value":"$128.0 million to $135.0 million"},{"label":"Guidance","value":"initiated"},{"label":"Result","value":"guidance update"}],"fact_type":"earnings_release"}],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}